Biotech Values

[apljack]

JAV: Beat me to it acgood. If the data are good and were mismanaged, then the FDA should accept it, IMO. Certainly, I would expect the FDA reviewes to scrutinize both analyses to ensure that the second one was correct.

Recall that the Ereska trial data missed by several 1/1000's of a point for the .05 stat sig level, so one data entry mistake could have caused the error.

That said, the co. can certainly be seen as inept in handling the data, the potential sale, and the lawyers are going to have a field day with this kind of error.

I lost alot of money here. Not litigious (I take repsonibility for my own investments) but damn angry that our shareholder value got hammered because of this type of F*%# up.

aj